RIGEL PHARMACEUTICALS INC

Rigel’s shares rose in premarket trading after the company announced a global licensing agreement for the recently approved breast cancer drug Veppanu. Rigel will pay $70m upfront and a further $15m after completion of transition activities; Arvinas and Pfizer can receive up to $320m in milestone payments plus tiered, sales-based royalties. Truist called the partnership strategically sensible and left its rating and price target unchanged. Before the price jump, Rigel shares had lost 38.8% year to date. » Więcej na de.investing.com

Rigel reported 2025 net product revenues of $232 million, a 60% increase versus 2024, and quarterly revenues of $65.4 million. The company has been profitable since Q3 2024, holds $155 million in cash and unveiled a four‑stage growth strategy. Initial phase‑1b data for R289 in low‑risk transfusion‑dependent MDS showed transfusion independence for >8 weeks in 6 of 18 evaluable patients (33%); the safety profile was overall favorable. For 2026 Rigel forecasts total revenue of $275–290 million, expects a positive net income and plans to select a phase‑2 dose and pursue further FDA discussions for R289. » Więcej na de.investing.com

Rigel Pharmaceuticals released preliminary Q4 2025 results showing revenue of about $69.8 million and gross product sales of $84.5 million, driven by TAVALISSE ($45.6m), GAVRETO ($10.2m) and REZLIDHIA ($9.6m). The company expects 2025 full-year revenue of roughly $294.3 million, up from $179.3 million in 2024, and projects 2026 revenue between $275 million and $290 million. An analyst from H.C. Wainwright reiterated a Buy rating with a $57 price target ahead of the March 3 official results release. » Więcej na finance.yahoo.com